Gregory F. Covino is a biotechnology finance and administration consultant. Since September 2021, he has served as a member of the Renovacor Inc. board of directors as the lead independent director and audit committee chairman. Renovacor is a clinical stage gene therapy biotechnology company. From November 2020 until August 2021, Covino served as an Executive Advisor at Novavax Inc., a novel vaccines company, from April 2021 until August 2021, and Executive Vice President, Chief Financial Officer from November 2020 until April 2021. Covino has also been Finance and IT Lead for Oncopeptides USA., a global oncology company based in Sweden, and interim controller of Unity Biotechnology, Inc., a company developing therapeutics for diseases of aging. From January 2019 until January 2020, Covino served as the Group Chief Financial Officer of the TESARO oncology division of GlaxoSmithKline (“GSK”) plc, a global healthcare company. Prior to the acquisition by GSK, Covino served as TESARO’s Chief Accounting Officer from July 2018 until January 2019. From March 2012 to July 2018, Covino served as the Chief Accounting Officer for Biogen Inc., a global biotechnology company. He also worked in Life Sciences at Boston Scientific, Inc from 2008-2012. 

Covino has been an adjunct professor at Bryant University and received his B.S. in Business Administration from Bryant, and has held Certified Public Accountant licensure in Massachusetts and Connecticut.